Coronary Artery Anomaly (CHD)

Categories: Cardiovascular diseases, Genetic diseases

Aliases & Classifications for Coronary Artery Anomaly

MalaCards integrated aliases for Coronary Artery Anomaly:

Name: Coronary Artery Anomaly 12 15 38
Coronary Artery Disease 12 44 15 72
Myocardial Ischemia 44 17 72
Coronary Arteriosclerosis 12 72
Coronary Heart Disease 12 72
Coronary Disease 12 44
Coronary Artery Disease, Susceptibility to 6
Congenital Anomaly of Coronary Artery 12
Coronary Artery Anomaly, Congenital 12
Coronary Artery Abnormality 12
Coronary Syndrome 15
Chd 12


External Ids:

Disease Ontology 12 DOID:11843 DOID:3393
UMLS 72 C0010054 C0010068 C0151744 more

Summaries for Coronary Artery Anomaly

MalaCards based summary : Coronary Artery Anomaly, also known as coronary artery disease, is related to lipid metabolism disorder and impotence, and has symptoms including tremor, angina pectoris and edema. An important gene associated with Coronary Artery Anomaly is PON1 (Paraoxonase 1), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Binding and Uptake of Ligands by Scavenger Receptors. The drugs Sulfasalazine and Fenoldopam have been mentioned in the context of this disorder. Affiliated tissues include heart, endothelial and testes, and related phenotypes are cardiovascular system and homeostasis/metabolism

Related Diseases for Coronary Artery Anomaly

Diseases in the Coronary Artery Anomaly family:

Coronary Artery Disease, Autosomal Dominant, 1 Coronary Artery Disease, Autosomal Dominant 2

Diseases related to Coronary Artery Anomaly via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1341)
# Related Disease Score Top Affiliating Genes
1 lipid metabolism disorder 32.5 SERPINE1 CRP APOB APOA1 ACE
2 impotence 32.0 NOS3 KNG1 EDN1
3 homocysteinemia 32.0 NOS3 CRP ALB
4 peripheral artery disease 31.9 NOS3 CRP APOB ACE
5 sleep apnea 31.9 NPPB NOS3 EDN1 CRP ACE
6 mitral valve insufficiency 31.8 NPPB NPPA ACE
7 glucose intolerance 31.8 IRS1 CRP APOB
8 end stage renal failure 31.7 CRP APOB ALB ACE
9 atrial fibrillation 31.7 PLAT NPPB NPPA CRP ACE
10 tetralogy of fallot 31.7 NPPB NPPA EDN1 CRP
11 body mass index quantitative trait locus 11 31.6 SERPINE1 PON1 NOS3 IRS1 CRP APOB
12 inferior myocardial infarction 31.6 PLAT PIK3C2A NPPB
13 peripheral vascular disease 31.6 SERPINE1 PLAT CRP APOB APOA1 ALB
14 heart valve disease 31.5 NPPB NPPA CRP ACE
15 anterolateral myocardial infarction 31.5 PLAT NPPB NPPA ACE
16 familial hyperlipidemia 31.5 SERPINE1 PON1 APOB APOA1
17 coronary artery vasospasm 31.5 PIK3C2A NOS3 EDN1
18 sexual disorder 31.5 NOS3 EDN1 ACE
19 pericardial effusion 31.5 PIK3C2A NPPB NPPA CRP
20 generalized atherosclerosis 31.5 CRP ACE
21 gas gangrene 31.5 TNNI3 PIK3C2A MB
22 intermittent claudication 31.5 SERPINE1 CRP ALB ACE
23 microvascular complications of diabetes 5 31.5 SERPINE1 PON1 NOS3 ALB ACE
24 left bundle branch hemiblock 31.4 TNNI3 NPPB ACE
25 cardiac arrest 31.4 TNNT2 PIK3C2A NPPB ALB ACE
26 arteriosclerosis 31.4 SERPINE1 PON1 EDN1 CRP APOB APOA1
27 kawasaki disease 31.3 NPPB CRP ALB
28 intermediate coronary syndrome 31.3 TNNI3 PLAT PIK3C2A MB CRP ACE
29 aortic coarctation 31.3 NOS3 EDN1 ACE
30 diastolic heart failure 31.2 NPPB NPPA NOS3 ACE
31 aortic valve disease 2 31.2 NPPB NPPA CRP ACE
32 carotid artery disease 31.2 CRP APOB APOA1 ACE
33 myocarditis 31.2 TNNI3 NPPB MB
34 atrial standstill 1 31.1 TNNT2 TNNI3 NPPB ACE
35 central serous chorioretinopathy 31.1 SERPINE1 PLAT
36 congestive heart failure 31.1 NPPB NPPA KNG1 EDN1 ADM ACE
37 ischemia 31.1 PON1 PLAT NOS3 MB KNG1 EDN1
38 systolic heart failure 31.1 NPPB EDN1 CRP ACE
39 kidney disease 31.1 SERPINE1 NPPB NPPA NOS3 EDN1 CRP
40 aortic valve insufficiency 31.1 PON1 NPPB ACE
41 diabetes mellitus, noninsulin-dependent 31.1 SERPINE1 PON1 PLAT NOS3 IRS1 EDN1
42 aortic valve disease 1 31.1 TNNI3 NPPB CRP APOB ACE
43 angina pectoris 31.1 PLAT PIK3C2A NPPB NOS3 EDN1 CRP
44 renal artery disease 31.1 NOS3 ACE
45 cardiogenic shock 31.1 PLAT PIK3C2A NPPB
46 diabetes mellitus 31.0 SERPINE1 PON1 PIK3C2A NOS3 IRS1 EDN1
47 mitral valve disease 31.0 NPPA NOS3 ACE
48 overnutrition 31.0 SERPINE1 IRS1 CRP APOB
49 congenitally corrected transposition of the great arteries 31.0 TNNT2 NPPB
50 endocarditis 31.0 TNNI3 PLAT PIK3C2A CRP ALB

Graphical network of the top 20 diseases related to Coronary Artery Anomaly:

Diseases related to Coronary Artery Anomaly

Symptoms & Phenotypes for Coronary Artery Anomaly

UMLS symptoms related to Coronary Artery Anomaly:

tremor, angina pectoris, edema, chest pain, equilibration disorder, other and unspecified angina pectoris, substernal pain

MGI Mouse Phenotypes related to Coronary Artery Anomaly:

# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.36 ACE ADM APOA1 APOB CRP EDN1
2 homeostasis/metabolism MP:0005376 10.25 ACE ADM ALB APOA1 APOB CRP
3 cellular MP:0005384 10.14 ADM ALB APOA1 APOB FABP3 IRS1
4 growth/size/body region MP:0005378 10.11 ACE APOB EDN1 IRS1 KNG1 MB
5 mortality/aging MP:0010768 10 ACE ADM ALB APOB EDN1 FABP3
6 adipose tissue MP:0005375 9.93 ACE FABP3 IRS1 NOS3 PIK3C2A SERPINE1
7 liver/biliary system MP:0005370 9.91 ACE ADM ALB APOA1 APOB FABP3
8 muscle MP:0005369 9.73 ADM ALB APOB EDN1 FABP3 IRS1
9 renal/urinary system MP:0005367 9.23 ACE ADM ALB EDN1 NOS3 NPPA

Drugs & Therapeutics for Coronary Artery Anomaly

Drugs for Coronary Artery Anomaly (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 989)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Sulfasalazine Approved Phase 4 599-79-1 5359476 5353980
Fenoldopam Approved Phase 4 67227-56-9, 67227-57-0 3341
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
Udenafil Approved, Investigational Phase 4 268203-93-6 6918523
Promethazine Approved, Investigational Phase 4 60-87-7 4927
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
Zolpidem Approved Phase 4 82626-48-0 5732
Cyproterone Acetate Approved, Investigational Phase 4 427-51-0
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
Gliclazide Approved Phase 4 21187-98-4 3475
Eplerenone Approved Phase 4 107724-20-9 150310 443872
Pravastatin Approved Phase 4 81093-37-0 54687
Acetaminophen Approved Phase 4 103-90-2 1983
Sodium citrate Approved, Investigational Phase 4 68-04-2
Probucol Approved, Investigational Phase 4 23288-49-5 4912
Glipizide Approved, Investigational Phase 4 29094-61-9 3478
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
Lovastatin Approved, Investigational Phase 4 75330-75-5 53232
22 Nutmeg Approved Phase 4
Digoxin Approved Phase 4 20830-75-5 30322 2724385
Salicylic acid Approved, Investigational, Vet_approved Phase 4 69-72-7 338
Cosyntropin Approved Phase 4 16960-16-0 16129617
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
Etomidate Approved Phase 4 33125-97-2 36339 667484
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
Bezafibrate Approved, Investigational Phase 4 41859-67-0 39042
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
Polyestradiol phosphate Approved Phase 4 28014-46-2
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
Propranolol Approved, Investigational Phase 4 525-66-6 4946
Apixaban Approved Phase 4 503612-47-3 10182969
Morphine Approved, Investigational Phase 4 57-27-2 5288826
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
Methylnaltrexone Approved Phase 4 916055-93-1, 83387-25-1 6603824
Remifentanil Approved Phase 4 132875-61-7 60815
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
Famotidine Approved Phase 4 76824-35-6 3325
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
Saxagliptin Approved Phase 4 361442-04-8 11243969
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
Glyburide Approved Phase 4 10238-21-8 3488
Linagliptin Approved Phase 4 668270-12-0 10096344
Thiopental Approved, Vet_approved Phase 4 76-75-5 3000715

Interventional clinical trials:

(show top 50) (show all 7535)
# Name Status NCT ID Phase Drugs
1 Randomized Placebo-controlled Crossover Trial of Endothelial Function Improvement in Subjects With History of Premature Coronary Artery Disease Unknown status NCT00917527 Phase 4 Atorvastatin
2 The Impact of Compound Danshen Dropping Pill for Coronary Heart Disease With Hypertension Patient Heart and Artery Structure and Function Unknown status NCT01825759 Phase 4 danshen dripping pill
3 Rosuvastatin Effect on Reducing Coronary Atherosclerosis Plaques Volume Evaluated by Multi-slice Spiral CT in Patients With Stable Coronary Heart Disease and Hyperlipidemia Unknown status NCT01382277 Phase 4 Rosuvastatin
4 Assessment of the Effects of Ezetimibe on Coronary Plaque Volume in Patients With Acute Coronary Syndrome Unknown status NCT01068093 Phase 4 Ezetimibe
5 The Effect of Tongguan Capsule for MicroRNA Profiles Between Qi-Stagnation and Qi-Deficiency in Coronary Heart Disease Patients With Blood Stasis Syndrome Undergoing Percutaneous Coronary Intervention Unknown status NCT02850627 Phase 4 Tongguan capsule;placebo capsule
6 Ischemia In Hemodialysed Patients And Outcome: Ivabradine Versus Carvedilol. A Randomized, Double Blind Study Unknown status NCT01425164 Phase 4 Ivabradine;Carvedilol
7 Comparison of Efficacy and Safety of Ivabradine Versus Metoprolol for Controlling Heart Rate Prior to 640-Slice Computed Tomographic Angiography in Elective Patients Unknown status NCT01755663 Phase 4 Ivabradine and Metoprolol
8 Comparison of Biolimus-eluting Biodegradable Polymer, Everolimus-eluting and Sirolimus-eluting Coronary Stents Unknown status NCT01268371 Phase 4
9 A Multi Center Registry to Evaluate Multiple Stenting Using by Everolimus-eluting Stents for Treatment of Long Coronary Artery Disease Unknown status NCT01147237 Phase 4
10 Randomized Controlled Clinical Study to Compare the Efficacy and Safety of Different Dose of Tirofiban in Interventional Treatment of Complex Coronary Artery Disease Unknown status NCT02294994 Phase 4 tirofiban
11 Clinical Evaluation of the Momo Cobalt-Chromium Coronary Stent System for the Treatment of Patients With Coronary Artery Disease Unknown status NCT01535625 Phase 4
12 Simultaneous Acquisition of Intravascular Ultrasound and Near Infrared Spectroscopy Data in the Coronary Artery Study Unknown status NCT02154295 Phase 4
13 Rosiglitazone Therapy In The Prevention Of Coronary Artery Disease In Patients With Impaired Glucose Tolerance Unknown status NCT00733174 Phase 4 Rosiglitazone;Placebo
14 The Efficacy of Lescol XL(Fluvastatin Extended Release 80 mg) on Atherosclerosis Progression in Patients With Newly Diagnosed Coronary Heart Disease Unknown status NCT01681199 Phase 4 Fluvastatin extended release tablet
15 Telmisartan vs Ramipril for Reduction of Inflammation and Recruitment of Endothelial Progenitor Cells After Acute Coronary Syndrome Unknown status NCT00702936 Phase 4 TELMISARTAN;RAMIPRIL
16 The Effects of Omega 3 and Vitamin E Supplementation on the Serum Antioxidant Enzymes and Gene Expressions of PGC-1a, h TERT, FOXOs and SIRTs in CAD Patients Unknown status NCT02011906 Phase 4
17 Graft Patency After FFR-guided Versus Angio-guided CABG: a Prospective, Multicenter, Multinational, Randomized (1:1) Controlled Trial Unknown status NCT01810224 Phase 4
18 Optimizing Timing of Coronary Artery Bypass Surgery in Patients Presenting With Acute Coronary Syndrome and Treated With Second Generation ADP Receptor Antagonist Unknown status NCT02627521 Phase 4 Ticagrelor
19 Bivalirudin in Stable Ischemic Heart Disease Patients Undergoing PCI Unknown status NCT02787317 Phase 4 bivalirudin;Heparin
20 Multicenter Trial on Clinical Utility of Acarbose in Patients With Ischemic Heart Disease Accompanied by Abnormal Glucose Regulation Unknown status NCT00858676 Phase 4 acarbose
21 A Randomised, Placebo Controlled, Double Blind, Cross-over, Single Center Clinical Study to Investigate the Effect of Heart Rate Reduction With Ivabradine on Vascular Elastic Properties and Endothelial Function in Patients With Stable Coronary Heart Disease Unknown status NCT01768585 Phase 4 Ivabradine;Placebo
22 Prospective, Randomized Study of the Platelet Inhibitory Efficacy of Ticagrelor Versus Prasugrel in Clopidogrel Low Responders After Percutaneous Coronary Intervention Unknown status NCT01456364 Phase 4 Ticagrelor;Prasugrel
23 Different Dosage of Domestic and Imported Clopidogrel on the Platelet Inhibition Ratio in Patients Undergoing PCI Unknown status NCT03006835 Phase 4 Clopidogrel
25 Comparison of Diabetes Mellitus and Non-diabetes Mellitus Patients for Surface Coverage After Two Types of Drug-eluting Stent Implantation (A Pilot Study) Unknown status NCT01021930 Phase 4
26 Prospective Multicenter Registry of Hybrid Coronary Artery Revascularization Combined With Surgical Bypass and Percutaneous Coronary Intervention Using Everolimus Eluting Metallic Stents Unknown status NCT02894255 Phase 4
27 Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy Unknown status NCT01869309 Phase 4 Prasugrel;Ticagrelor
28 Study of Curative Effect Evaluation of Shexiang Baoxin Pill on Coronary Artery Disease Not Amenable to Revascularization on the Basis of Western Medicine Therapy Unknown status NCT03072121 Phase 4 Shexiang Baoxin pill;SBP placebo;Aspirin Enteric-coated Tablets;Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet;Atorvastatin Calcium;Isosorbide Mononitrate Tab 20 MG;Metoprolol Tartrate Tab 25 MG;Trimetazidine Dihydrochloride Tablets
29 OCT Evaluation of Stent Struts Re-endothelization in Patients With Acute Coronary Syndromes: a Comparison of the Intrepide™ Stent vs. Taxus™ Unknown status NCT00914420 Phase 4
30 The 001-DIOR Multicenter Registry (A Novel Percutaneous Coronary Intervention With the New Paclitaxel-eluting Balloon DIOR in Ostial Bifurcated Lesions) Unknown status NCT01375465 Phase 4
31 Effect of Preoperative Aspirin in Patients Undergoing Off-pump Coronary Artery Bypass Grafting: A Double-blind, Placebo-controlled, Randomized Trial Unknown status NCT03049085 Phase 4 Aspirin;vitamin C
32 Ranolazine, Ethnicity and the Metabolic Syndrome - REMS Study Unknown status NCT01304095 Phase 4 Ranolazine
33 Nanjing First Hospital, Nanjing Medical University Unknown status NCT01171911 Phase 4 Nicardipine , Esmolol
34 The Prediction of Extent and Risk Profile of Coronary Atherosclerosis (Examined by Intravascular Ultrasound, Virtual Histology and Optical Coherence Tomography) and Their Changes During Lipid-lowering Therapy Based on Non-invasive Techniques. Unknown status NCT01773512 Phase 4 Rosuvastatin
35 Study of Curative Effect Evaluation of DanLou Tablet on Coronary Artery Disease Not Amenable to Revascularization on the Basis of Western Medicine Therapy Unknown status NCT03072082 Phase 4 Danlou Tablet;DanLou Tablet placebo;Aspirin Enteric-coated Tablets;Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet;Atorvastatin calcium;Isosorbide Mononitrate Tab 20 MG;Metoprolol Tartrate Tab 25 MG;Trimetazidine Dihydrochloride Tablets
36 Phase 4 Study of Patients Receiving BNP or NTG (IV) During Angioplasty, Re-examined 24 Hours Later Using the Flow-mediated Brachial Artery Dilation Study, and Blood Assays for Pro BNP and ET1 Unknown status NCT00262574 Phase 4 Nesiritide,
37 Apposition Assessed Using Optical Coherence Tomography of Chromium Stents Eluting Everolimus From Cobalt Versus Platinum Alloy Platforms. Unknown status NCT01776567 Phase 4
38 A Comparative Evaluation of Efficacy and Safety in the 3-Months DAPT Group vs. the 6-Months DAPT Group of Patients Treated With the Coroflex ISAR Stent; A Prospective, Multicenter, Randomized, Open-Label Clinical Trial Unknown status NCT02609698 Phase 4 3 months DAPT;6 months DAPT
39 Impact of Periodontal Therapy in Flow-mediated Dilation and Serum Levels of Cardiovascular Risk Biomarkers in Coronary Artery Disease Patients: 12 Months Randomized Controlled Trial Unknown status NCT01609725 Phase 4
40 Phase IV: A Comparison of Reduced-dose Prasugrel and Clopidogrel in Elderly Patients With Acute Coronary Syndrome Undergoing Early Percutaneous Coronary Intervention (PCI) Unknown status NCT01777503 Phase 4 prasugrel;Clopidogrel
41 Impact of Stent Platform on Shear Stress Distribution and Subsequent Vessel Healing After Drug-eluting Stent Implantation (SHEAR DES) Unknown status NCT01942044 Phase 4
42 Pilop Trial of OCT-determined Coverage of Permanent or Polymer-free Sirolimus Eluting Stent at Long Term Unknown status NCT01260558 Phase 4
43 Prospective, Randomized Trial of Limus-Eluting Stents With Biodegradable or Permanent Polymer Coatings Unknown status NCT01068106 Phase 4
44 Randomized Comparison of Biolimus-Eluting and Everolimus-Eluting Stents With Optical Coherence Tomography Guided Stent Implantation in ST Elevation Myocardial Infarction.A 9-Month Angiographic and Optical Coherence Tomography Follow-up. Unknown status NCT00888758 Phase 4
45 A Randomized, Double-blind, Multi-centered, Placebo-controlled Trial to Examine Effects of Heart-protecting Musk Pill on Clinical Outcome in Patients With Chronic Stable Coronary Artery Disease Unknown status NCT01897805 Phase 4 Heart-protecting Musk Pill;Placebo
46 Randomized Trial of the Association Between Low-Dose Statins and Nutraceuticals in High-intEnsity Statin-intoleRant patiENts With Very High Risk Coronary Artery diseasE Unknown status NCT02001883 Phase 4 Association low-dose statin and nutraceuticals
47 The Beneficial Role of Percutaneous Coronary Intervention Over Optimal Medical Therapy in Elderly Patients (Age > 75 Years Old) With Coronary Artery Disease: a Randomized Controlled Study Unknown status NCT01508663 Phase 4 ARB, CCB, ACE-inhibitor, statin, Nitrate, Antiplate etc.
48 A Prospective Multicenter Trial Evaluating Helios Biodegradable Polymer Sirolimus-eluting Stent Safety and Effectiveness in Treatment of Coronary Artery Disease Unknown status NCT01880879 Phase 4
49 Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients With Stable Angina, NSTEMI and STEMI Undergoing PCI Unknown status NCT02012140 Phase 4 ticagrelor
50 Use of Hypertonic Versus Isotonic Solutions in Off Pump Coronary Artery Bypass Graft Surgery Targeting the Left Marginal Branch Unknown status NCT01463917 Phase 4 Hypertonic solution;Isotonic

Search NIH Clinical Center for Coronary Artery Anomaly

Inferred drug relations via UMLS 72 / NDF-RT 51 :

Atorvastatin calcium
Cerivastatin sodium
Cholestyramine Resin
Colesevelam hydrochloride
Colestipol Hydrochloride
Dextrothyroxine Sodium
Fish Liver Oils
Fluvastatin sodium
Isosorbide Dinitrate
Isosorbide Mononitrate
Pravastatin Sodium
Thallous Chloride

Cell-based therapeutics:

LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Coronary Artery Anomaly cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: coronary artery disease

Genetic Tests for Coronary Artery Anomaly

Anatomical Context for Coronary Artery Anomaly

MalaCards organs/tissues related to Coronary Artery Anomaly:

Heart, Endothelial, Testes, Kidney, Bone, Liver, Lung

Publications for Coronary Artery Anomaly

Articles related to Coronary Artery Anomaly:

(show top 50) (show all 30983)
# Title Authors PMID Year
Coronary artery disease and a functional polymorphism of hTERT. 38 71
16890917 2006
A common mutation of the insulin receptor substrate-1 gene is a risk factor for coronary artery disease. 38 71
10591678 1999
The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. 38 71
8770857 1996
A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. 38 71
8675673 1995
Paraoxonase-1 is a major determinant of clopidogrel efficacy. 71
21170047 2011
Paraoxonase 1 polymorphisms and survival. 71
15241482 2004
Impaired endothelial function in never-treated hypertensive subjects carrying the Arg972 polymorphism in the insulin receptor substrate-1 gene. 71
15240653 2004
G972R IRS-1 variant impairs insulin regulation of endothelial nitric oxide synthase in cultured human endothelial cells. 71
14707024 2004
Genetic polymorphism PC-1 K121Q and ethnic susceptibility to insulin resistance. 71
14671192 2003
The Arg972 variant in insulin receptor substrate-1 is associated with an atherogenic profile in offspring of type 2 diabetic patients. 71
12843189 2003
Genetic analysis of Paraoxonase (PON1) locus reveals an increased frequency of Arg192 allele in centenarians. 71
12082503 2002
Paraoxonase gene cluster is a genetic marker for early microvascular complications in type 1 diabetes. 71
11918623 2002
Paraoxonase-1 L55M polymorphism is associated with an abnormal oral glucose tolerance test and differentiates high risk coronary disease families. 71
11889198 2002
Paraoxonase (PON1) polymorphisms in farmers attributing ill health to sheep dip. 71
11888590 2002
Paraoxonase gene Gln192Arg (Q192R) polymorphism is associated with coronary artery spasm. 71
11810302 2002
LL-paraoxonase genotype is associated with a more severe degree of homeostasis model assessment IR in healthy subjects. 71
11788650 2002
Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. 71
11335891 2001
The BB-paraoxonase genotype is associated with impaired brachial reactivity after acute hypertriglyceridemia in healthy subjects. 71
11238489 2001
The Gly-->Arg972 amino acid polymorphism in insulin receptor substrate-1 affects glucose metabolism in skeletal muscle cells. 71
10843189 2000
The Gly972-->Arg amino acid polymorphism in IRS-1 impairs insulin secretion in pancreatic beta cells. 71
10430617 1999
Prevalence of variants in candidate genes for type 2 diabetes mellitus in The Netherlands: the Rotterdam study and the Hoorn study. 71
10084586 1999
A variant of paraoxonase (PON1) gene is associated with diabetic retinopathy in IDDM. 71
9661650 1998
Paraoxonase-gene polymorphisms associated with coronary heart disease: support for the oxidative damage hypothesis? 71
9443884 1998
The Arg192 isoform of paraoxonase with low sarin-hydrolyzing activity is dominant in the Japanese. 71
9385372 1997
Paraoxonase polymorphism (Gln192-Arg) is associated with coronary heart disease in Japanese noninsulin-dependent diabetes mellitus. 71
9215303 1997
Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. 71
9011577 1997
A common amino acid polymorphism in insulin receptor substrate-1 causes impaired insulin signaling. Evidence from transfection studies. 71
8647950 1996
Insulin resistance: interactions between obesity and a common variant of insulin receptor substrate-1. 71
7623569 1995
Aminoacid polymorphisms of insulin receptor substrate-1 in non-insulin-dependent diabetes mellitus. 71
8104271 1993
Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. 71
7916578 1993
The molecular basis of the human serum paraoxonase activity polymorphism. 71
8098250 1993
Cloning and increased expression of an insulin receptor substrate-1-like gene in human hepatocellular carcinoma. 71
1311924 1992
Genetic engineering with endothelial nitric oxide synthase improves functional properties of endothelial progenitor cells from patients with coronary artery disease: an in vitro study. 9 38
19479297 2009
Paraoxonase variants relate to 10-year risk in coronary artery disease: impact of a high-density lipoprotein-bound antioxidant in secondary prevention. 9 38
19778663 2009
Plasma brain natriuretic peptide at rest and after adenosine-induced myocardial ischemia in normotensive and essential hypertensive patients with suspected coronary artery disease. 9 38
18951935 2009
Association of beta1-adrenergic receptor genetic polymorphism with mental stress-induced myocardial ischemia in patients with coronary artery disease. 9 38
18413560 2008
Influence of left ventricular filling pattern on exercise-induced changes of natriuretic peptides in patients with suspected coronary artery disease. 9 38
17442418 2008
Presence and severity of coronary artery disease and changes in B-type natriuretic peptide levels in patients with a normal systolic function. 9 38
17002921 2006
B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide - Diagnostic role in stable coronary artery disease. 9 38
18651043 2006
Usefulness of high-sensitivity IL-6 measurement for clinical characterization of patients with coronary artery disease. 9 38
15900566 2005
[Role of cholesteryl ester transfer protein activity and genetic polymorphism in ischemic heart disease in type 2 diabetic patients]. 9 38
15382463 2004
[New biological markers for acute coronary artery disease]. 9 38
14978429 2003
[Plasminogen activator inhibitor-1 (PAI-1), ischemic heart disease and diabetes mellitus]. 9 38
12728597 2003
Acute effects of heparin administration on the ischemic threshold of patients with coronary artery disease: evaluation of the protective role of the metabolic modulator trimetazidine. 9 38
11823078 2002
Long-term treatment with perindopril ameliorates dobutamine-induced myocardial ischemia in patients with coronary artery disease. 9 38
11855668 2002
[Endothelin-1 in coronary artery disease]. 9 38
11770304 2001
Evaluation of the effects of aspirin combined with angiotensin-converting enzyme inhibitors in patients with coronary artery disease. 9 38
11020393 2000
Soluble L-selectin level is a marker for coronary artery disease in type 2 diabetic patients. 9 38
10587840 1999
Short-term effect of exercise on platelet factor 4 in normal subjects and in patients with coronary artery disease. 9 38
10686775 1999
Atrial natriuretic peptide attenuates pacing-induced myocardial ischemia during general anesthesia in patients with coronary artery disease. 9 38
9972741 1999